Arcturus Therapeutics
ARCT
24 hedge funds and large institutions have $7.63M invested in Arcturus Therapeutics in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
4% more funds holding
Funds holding: 23 → 24 (+1)
0.33% less ownership
Funds ownership: 4.24% → 3.91% (-0.33%)
17% less capital invested
Capital invested by funds: $9.16M → $7.63M (-$1.53M)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
91% less call options, than puts
Call options by funds: $1K | Put options by funds: $11K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$36.2K |
| 2 |
LCM
Leisure Capital Management
Costa Mesa,
California
|
+$23.8K |
| 3 |
FAM
Formidable Asset Management
Cincinnati,
Ohio
|
+$14.5K |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$14K |
| 5 |
PCM
Prelude Capital Management
New York
|
+$8.72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$432K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$235K |
| 3 |
Two Sigma Investments
New York
|
-$25K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19.4K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$17.9K |
ARCT Hedge Fund Activity: Q3 2017 in Review
24 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2017, worth a combined $7.63M — down 17% from $9.16M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ARCT positions and 5 closed out — a net gain of 1 holder — while 2 added to existing stakes and 7 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $36.2K. The largest seller was Knoll Capital Management, cutting an estimated $432K.
- 24 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2017, up from 23 in Q2 2017.
- Funds reported $7.63M of Arcturus Therapeutics stock for Q3 2017, down 17% quarter-over-quarter.
- 6 funds opened new Arcturus Therapeutics positions in Q3 2017 and 5 closed out, a net change of +1 holder.
- The largest Arcturus Therapeutics buyer in Q3 2017 was Morgan Stanley, an estimated $36.2K added.
- The largest Arcturus Therapeutics seller in Q3 2017 was Knoll Capital Management, an estimated $432K sold.
Based on aggregated 13F filings for Q3 2017.